Innovating Next-Generation Therapeutics with Advanced Polymers
Pleryon is a world pioneer in developing polymer-based therapeutics. Our mission is to develop novel treatments for multiple unmet medical needs by utilizing our proprietary technology that controls the 2D sequence and 3D structure of extra-large polymeric molecules. By targeting diseases through physical, mechanical and biological means, we are pioneering a new way to treat complex and multifactorial diseases.
Product Pipelines
P001X
Synthetic lubricating polymer for the treatment of osteoarthritis
Osteoarthritis (OA) affects over 500 million patients worldwide and remains a leading cause of disability in older adults. Despite its substantial burden on both individual and health systems, therapeutic innovation in osteoarthritis has not made significant progress. As a result, the demand for effective treatment solutions continues to rise, and has driven the global market for osteoarthritis approaching $6 billion, underscoring the unmet need and immense market potential.
P001X is a first-in-class, intra-articular injectable therapy for osteoarthritis. It is a synthetic polymer inspired by lubricin with a novel mechanism of action. In pre-clinical studies, P001X demonstrated greater lubricity than native lubricin, and showed efficacy with a favorable safety profile across multiple in vitro and in vivo models. The manufacturing process is robust and readily scalable to support late-stage development and commercialization.
Publications and Conference Presentations
Synthetic lubrication of bone interfaces for late-Stage osteoarthritis treatment
Z Sun, L Bonassar, D Putnam , Langmuir 2025, 41, 32, 21627–21635
Lubricin-Inspired Polymer Achieves Superior Cartilage Boundary Lubrication
S Witt, Z Sun, Y Yu, L Bonassar, ORS 2025 Poster#:1328,Session:PS2-096 (Download)
Boundary mode lubrication of articular cartilage with a biomimetic diblock copolymer
Z Sun, E Feeney, Y Guan, S Cook, D Gordon, L Bonassar, D Putnam, Proceedings of the National Academy of Sciences. 2019, 116(25), 12437-12441.
The influence of block length on articular cartilage lubrication with a diblock bottlebrush copolyme
Z Sun, L Bonassar, D Putnam, ACS Applied Materials & Interfaces. 2019, 12(1), 330-337
P002
Synthetic lubricating polymer for the treatment of dry eye disease
Dry eye disease (DED) is a major global unmet need, impacting over 300 million patients. Existing therapies had significant limitations including low patient satisfaction rate, highlighting the urgent demand for more effective options. The global dry eye market exceeds $5 billion, reflecting its substantial commercial potential.
P002 is a synthetic polymer-based eye drop inspired by the structure of the natural glycoprotein lubricin. Leveraging Pleryon’s proprietary polymer engineering platform, P002 is designed to mimic the core structure and function of natural lubricin, providing long-acting boundary lubrication and protection to the ocular surface. Preclinical studies have demonstrated excellent efficacy and safety profiles across multiple in vitro and in vivo models. Furthermore, the manufacturing process is robust and readily scalable to support late-stage development and commercialization.
Publications and Conference Presentations
Lubricating synthetic diblock polymer for the treatment of dry eye disease
Y Yu, Z Sun, Y Chau, K Velmurugan, 2025 ARVO, #A0523 or Investigative Ophthalmology & Visual Science June 2025, Vol.66, 1601. (Download)
M007
Microstructure-Controlled Hydrogel for Regenerative Medicine
M007 is a state-of-the-art regenerative medicine.